Japan· JP-3961004F2010
クロルプロパミド
A chlorpropamide product containing クロルプロパミド, registered in Japan, on the national reimbursement list. The same ATC class is registered in 3 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Chlorpropamide is registered in 3 of 19 countries.
Countries holding a registration under ATC A10BB02 (chlorpropamide), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 1 of them publish a price we can compare per daily dose
Chlorpropamide · ATC A10BB02
3 / 19 countries
- Finlandprice
- Japan
- United Kingdom
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- クロルプロパミド
- Manufacturer
- —
- Country
- Japan (JP)
- ATC code
- A10BB02
- ATC class
- Chlorpropamide
- Defined daily dose
- 0.375 g, O
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
542 interactions on record for chlorpropamide.
Graded by severity as the source publishes them — 20 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Chlorpropamide · interactions on record
542 records
- 20 severe
- 454 moderate
- 53 minor
- 15 info
Most severe, free to view
- MiconazoleA07AC01severe
- Magnesium carbonateA02AA01moderate
- Magnesium oxideA02AA02moderate
- Magnesium hydroxideA02AA04moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Chlorpropamide in 1 other country
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/4e474f8e-fe8e-4200-bdce-1fdfc9247c5d GET /v1/drugs/4e474f8e-fe8e-4200-bdce-1fdfc9247c5d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "２５０ｍｇ１錠",
"marks": "局",
"source": "mhlw",
"remarks": null,
"yj_code": "3961004F2010",
"category": "内用薬",
"price_yen": null,
"generic_name": "クロルプロパミド",
"product_name_jp": null,
"therapeutic_class": "3961",
"transitional_expiry": null
}See everything about chlorpropamide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.